MIRA Pharma Consolidates Global Rights to MIRA-55 and SKNY-1
Decision brief
Answer first · skim in under a minute
MIRA Pharmaceuticals amends its MIRALOGX license to secure worldwide exclusive development and commercialization rights for MIRA-55 and SKNY-1, without altering core economics. The move strengthens IP control and follows peer-reviewed data on SKNY-1's obesity and nicotine addiction potential.
MIRA Pharmaceuticals NASDAQ MIRA consolidates worldwide exclusive development and commercialization rights to MIRA-55 and SKNY-1. The June 3, 2026 amended MIRALOGX license is disclosed in an SEC Form 8-K and a same-week press release.
Contents9 sections
Key Takeaways
- Amended license dated June 3, 2026 grants MIRA worldwide exclusive rights to MIRA-55 and SKNY-1.
- Rights include development, manufacture, sale, commercialization, sublicensing, and IP enforcement.
- MIRA says the structure now covers Ketamir-2, MIRA-55, and SKNY-1 globally.
- MIRA-55 and SKNY-1 remain pre-IND; clinical efficacy in humans is not yet established.
What changed in the MIRALOGX license?
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) filed a current report stating that on June 3, 2026 it entered an Amended and Restated Exclusive License Agreement with MIRALOGX LLC. The filing is available as a Form 8-K on SEC EDGAR.
Under that agreement, MIRALOGX granted worldwide exclusive rights under intellectual property covering the MIRA-55 and SKNY-1 programs, including rights to develop, manufacture, use, sell, offer for sale, commercialize, and sublicense covered products.
Why does a unified global rights structure matter?
The company's June 4, 2026 exhibit press release says MIRA now controls global development and commercialization rights across Ketamir-2, MIRA-55, and SKNY-1. Management framed the cleanup as preparation for Ketamir-2 Phase 2a work and IND filings for MIRA-55 and SKNY-1.
The Exhibit 99.1 press release also emphasizes worldwide sublicensing and enhanced IP enforcement as tools for future partnering.
What is known about SKNY-1 scientifically?
Peer-reviewed preclinical work indexed on PubMed (PMID 42196303) describes SKNY-1 as a THCV analog that produced weight loss, lipid normalization, and reduced reward-associated behaviors in an mc4r zebrafish obesity model. That is animal data only and does not establish human efficacy or safety.
- Asset class: cannabinoid-pathway analog (THCV-related).
- Model: mc4r(G894C) zebrafish obesity model.
- Human status: IND-enabling path claimed by company; no FDA approval.
What should BD and investor teams track next?
Near-term diligence items are IND submission timing for MIRA-55 and SKNY-1, Phase 2a progress for Ketamir-2, and any sublicense announcements that use the new worldwide rights. Cash runway and dilution risk remain material for a clinical-stage NASDAQ microcap even when IP ownership is cleaned up.
What remains unproven?
The 8-K does not publish new clinical efficacy tables for MIRA-55 or SKNY-1. Worldwide exclusivity improves partnering optionality; it does not prove that either asset will clear IND, enroll a Phase 1 cohort, or reach a registrational endpoint.
Related NovaPharma coverage
- FDA guidance on sharing potential NDA patent information
- Pfizer berobenatide obesity drug Vesper-3 data
- Danuglipron Phase 3 and Pfizer Phase 2b obesity trial
Frequently Asked Questions
What did MIRA Pharmaceuticals consolidate?
On June 3, 2026, MIRA entered an Amended and Restated Exclusive License Agreement with MIRALOGX LLC granting worldwide exclusive rights to develop, manufacture, commercialize, and sublicense MIRA-55 and SKNY-1.
Did the MIRA license change deal economics?
Company communications state the amended agreement consolidates global rights and IP enforcement without describing a material change to previously disclosed economic terms in the June 2026 Form 8-K summary.
What are MIRA-55 and SKNY-1 being developed for?
Company materials position MIRA-55 toward chronic inflammatory pain and SKNY-1 toward obesity and addiction-related disorders. A PubMed report describes SKNY-1 as a THCV analog studied in a zebrafish obesity model.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for MIRA-55.
Unlock full calendar →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
